secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bluejay Diagnostics, Inc. (BJDX)
CIK:        0001704287
Form:       8-K
Filed at:   2026-04-07T23:59:59+00:00
Accession:  0001213900-26-040728
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bluejay Diagnostics completes 624 of 750 patient enrollments in SYMON-II sepsis trial
--------------------------------------------------------------------------------

- SYMON-II pivotal trial for Symphony IL-6 sepsis triage test enrolled 624 of 750 target patients.
- Enrollment completion expected within 2-3 months, subject to site activity and patient flow.
- Inclusion and exclusion criteria have not caused significant patient exclusions, per CEO Neil Dey.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1704287/000121390026040728/0001213900-26-040728-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1704287/000121390026040728/ea0285343-8k_bluejay.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-040728

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer